Concepedia

Peng Peng

PP

Statistics

Publications

1

Citations

22

H-Index

1

Active since

2022

Affiliations

China Pharmaceutical University(Current)

Peng Peng is an author at China Pharmaceutical University specializing in drug discovery, oncology, and cancer biology.

ORCID

Top concepts

Publications per year

2022–2022

1

Publications

1

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer

Peng Peng, Xiaoyan Qiang, Guoyu Li et al. · Molecular Cancer Therapeutics · 2022 · 22 citations · Full text

, , +13

1–1 of 1